ADP

You live most of your life in your mind, make sure it is a nice place to be! Engineer, MBA-Fin.,Lovely family, Inspired by BKS Sister Shivani - OM SHANTI! SIP.

[ADP @Ajay_Pokiya]

@sapnareddy889 Even if not lucky to find and hold 100x in direct stock investment, investment in good MF @20% CAGR for 25 years will give return of 100x.

[Equity Insights Elite @EquityInsightss]

Interesting Data

Indian households currently have only 22% of their financial assets in market linked instruments

Deposits still remain the largest component at 35%

Mutual Fund AUM is projected to grow from 74 lakh Cr in FY26 to 141 lakh Cr by FY30E (18% CAGR)

Total demat accounts have grown from 35.9 Mn in FY19 to 224.3 Mn in FY26 (30% CAGR)

Retail investor AUM has grown from 7.1 lakh Cr in Mar'21 to 20 lakh Cr in Mar'26

Total AUM increased from 32.1 lakh Cr to 73.7 lakh Cr during the same period

Retail share has moved from 22.1% in Mar'21 to 27.1% in Mar'26

This clearly shows that retail investors are becoming a much bigger part of India’s capital market ecosystem

[ADP @Ajay_Pokiya]

@EquityValueIn Excellent 👍.
Keep sharing such incremental rate of change ideas for further deep research.

[ValueEquity @EquityValueIn]

Businesses I was reading about this week , things that I heard and found interesting across pharma , chemicals and IT

1) Suven Life Sciences may be entering an inflection point zone that can reward decades of R&D , again it is a " big may" as many of their drugs in R&D are reaching the phase 3( 2/5 ) where if they are able to crack it , things will change big time, but you have to see this as a biotech investment with binary outcomes , winner takes it all , looser has to fall , there is no in between , so that affects the amount of capital that can be allocated

Masupirdine (SUVN-502) - Alzheimer's Samelisant (SUVN-G3031) - Day time sleepiness /Narcolepsy , they are presenting the data soon at the global conference as well

These 2 are the main molecules that are entering the Phase-3 crucial stage where now if passed through can go to commercial

Now what is also interesting is some very interesting accumulation has happened by some good names probably pre empting the success of this and sizing limited risk , Prashant Jain 3P investment mangers , Sandeep tandon from Quant and Sunil Singhania Again these are very uncertain investments and most of the outcome nature is binary in nature , but worth reading

2) Biocon - The elephant may be able to dance , there is a clear tactical shift in how management is talking and the re focus on aligning to the path of profitable growth that may see a comeback post a very painful last few years

Quoting the management ( Q4FY26 concall )

"We are now moving from a phase of integration and investment to one focused on execution, operating leverage and value creation. From a capital and investment perspective, the heavy lifting is largely done and behind us. Over the past few years, we have invested materially to build global scale capabilities and capacity, particularly in biosimilars, insulins, peptides and complex generics. As we stand today, this major investment phase is substantially complete. The emphasis now is on improving utilization, expanding margins and driving steady improvement in return on capital employed"

Now focusing on sweating the assets , generate cash and focus on reduction in interest costs

Now how will this happen ? They have a very strong launch pipeline that is going into FY27 where H2 they may start to see tangible gains from it from an EBITDA point of view

Liraglutide Approvals in this Quarter , Yesintek
( Biosimilar to stelara which is a very expensive drug ) is also seeing increased traction across the channel
Bosaya and Aukelso also launched , will keep seeing how the sales data comes

why I think it is worth seeing because , Biosimilars good launches have happened , generics is improving , and they say syngene worst is over

And these business interest me where there is a decade of frustrated shareholders with 0 returns ,because the odds are in favor to make money if things actually turn

3) Chemicals - We are seeing the Anti involution trends play out in many commodity chemicals , this is not directly helping profits , but it is helping to stabilize industry structures that were subject to very bad market economics and that helps to improve realizations on an overall basis , this plus the Yuan factor , plus the prices being higher

We have been very positive on the Amines duo's since Late April ( mentioned in the rate of change tracker ) it has already played out well , but one more thing is there is a long term correlation I ran between Alkyl and Balaji , and Alkyl has always had a premium to Balaji , and that has not been the case in the last 5 months , so Alkyl may see a stronger catch up as well , but we spotted this in April and this has done a decent bit

4) IT , I think market is trying to recognize profit pool shifting to companies that are pivoting , after the Accenture earnings debacle, I was watching price behavior , laregecap was hit the worst , companies like rategain , indegene ( ones we like ) were in green , and coforge was barely down 3% , market is starting to see who are the incremental probable leaders , and we must stay in those places , difference will only get wider

5) Sentiment check : Lot of my industry friends had attended major brokerage conferences last week ( ICICI , CITI, GS) sentiment has improved after FII tax cut but situation from foreigners is still mixed , and that is purely a loop of underperformance , and relative growth , power and DC related companies halls remain filled till the lobby , while most others were relatively not that filled , but I do think this will turn much sooner than we think , while domestic money remains stable , some large IPO's will allow lot of foreign inflows which should be good from incremental flows POV

If you liked reading this type of post and my weekly thoughts , do let me know, can write like this more often !

[Equity Insights Elite @EquityInsightss]

J Curve PAT companies - FY22-26 PAT trend

All these companies have been multibaggers

The common factor? A sharp J Curve in earnings

MCX PAT moved from 143 Cr in FY22 to 1,332 Cr

BSE PAT moved from 245 Cr in FY22 to 2,487 Cr

CarTrade Tech moved from loss to a PAT of 244 Cr

Acutaas PAT moved from 72 Cr in FY22 to 356 Cr

Thangamayil PAT moved from 39 Cr in FY22 to 352 Cr

TD Power PAT moved from 71 Cr in FY22 to 239 Cr

For many of them, FY22-24 was a steady/transition phase, but from FY25-26, earnings scaled meaningfully

Once earnings inflection becomes visible, Re-rating + Earnings growth can create massive wealth

[ValueEquity @EquityValueIn]

My take on position sizing , very less spoken about when it comes to process building

Understanding this opens up lot more non linearity of gains

[Vishan @vishan_29]

RateGain - From SaaS Player to AI-Powered Travel Giant 🔥

FY26 was the year RateGain changed its identity. Targeting $1 Bn revenues by FY31. 🚀

The company completed the Sojern acquisition, integrated Adara, and built what it claims is the world's largest travel intent data platform with 320+ data partners, 1.5B+ travel graph IDs and 13,000+ customers.

The goal is clear: become the operating system for travel revenue growth.

🔶️ Building the Moat

• The Sojern-Adara integration is complete, cost synergies have already reached $15M annually, and customer migration to a unified platform is on track by Q2 FY27

• Management believes no competitor matches its combination of:
>> Travel intent data
>> Distribution infrastructure
>> AI-powered commercial intelligence

🔶️ AI Is Becoming the Product

• RateGain is moving from software tools to AI agents

• Early outcomes:
>> UNO VIVA: Up to 40% higher hotel revenues
>> AI Concierge: 300% increase in ancillary revenue and 75% higher NPS
>> Agentic ARI: 30-40% reduction in distribution traffic
>> AI agents being built for marketing, revenue management and distribution workflows

🔶️ Growth Engines Firing

• Martech remains the biggest opportunity, driven by Sojern and Adara

• Distribution is evolving beyond connectivity with launches like Rate IQ, Agentic ARI and RG Pay

• DaaS continues winning marquee airline customers including Singapore Airlines, Vietnam Airlines, Philippine Airlines, Air Serbia and others

🔶️ Stronger Balance Sheet

• Repaid $31.5M (25.2%) of acquisition debt
• Net debt reduced to ₹722 Cr
• Cash balance at ₹199 Cr
• Debt-free target by FY28

🔶️ FY27 - Monetization Begins

Guidance suggests the next phase is execution:

• Revenue: ₹3,000-3,100 Cr
• Growth: 65-70%
• Organic Growth: 12-15%
• EBITDA: ₹650-700 Cr (21.5-22.5% margin)
• DaaS growth: 10-14%
• Martech growth: 12-15%
• Sojern expected to grow 30%+

🔶️ Key Takeaway

FY26 was about assembling the pieces - data, AI, customers and global scale. FY27 is about monetizing them.

With a massive travel-data moat, accelerating AI adoption, 13,000+ customers and improving cash flows, RateGain is positioning itself for its stated ambition of becoming a $1B revenue company by FY31. 🔥

Src - @concall_in

👉 Follow @vishan_29 for more updates.

🔴 Disclaimer: No recommendation. For educational purposes only.

[Ankush Prajapati @Mf360WW]

The stock market doesn't punish ignorance immediately, it compounds mistakes silently.

Avoid these 10 errors, and you're already ahead of most investors.

[Neel Chhabra @NeelChhabra]

India's share of the global aerospace supply chain is moving from roughly 2% toward 10% directionally.

This isn't China+1 in the consumer-electronics sense (cost arbitrage, tariff avoidance). Aerospace supply chain diversification is driven by a different and arguably more durable logic... single-source risk concentration. Boeing and Airbus learned during COVID and subsequent supply shocks (Spirit AeroSystems' 2024 quality crisis being the most visible recent example) that having too much of the supply base concentrated in too few qualified suppliers is itself a tail risk to production rate. The OEMs are actively seeking to qualify new geographic suppliers not because India is cheaper (though it helps), but because supply chain single-points-of-failure became existential during 2020-2024. This is a structurally different and stickier kind of tailwind than cost arbitrage, because it doesn't reverse when Indian wages rise... it's about resilience, not just price.

The 5-10 year qualification cycle is the other side of this coin... it means this reshoring wave, once a supplier is qualified, is sticky almost by construction. OEMs don't re-shop qualified aerospace suppliers the way they'd re-shop a commodity component vendor, the switching cost itself becomes the moat. So the macro trend here isn't really "India is getting cheaper aerospace work" it's "India is becoming permanently embedded in aerospace supply chains because the cost of re-qualifying elsewhere exceeds any savings from doing so."

[ADP @Ajay_Pokiya]

@AimInvestments YES

[ValueEquity @EquityValueIn]

Reliance Industries , New energy and AI integration source: MS

Lets see what we can hear from the AGM today

[Rishi Bagree @rishibagree]

The cycle of life !!!

[krishan sharma @krishan_sharmaa]

A few months ago, I sold all my IT holdings
#TCS, #Infosys, and #HCLTech.

Today, I started buying them again.

Why?
Honestly, I don’t know.

I don’t have a detailed spreadsheet proving that this is the perfect time.
I don’t have a sophisticated model forecasting the next three years.
I don’t have evidence that these stocks will outperform.

👉What I do have is hope.

Hope that companies which have survived multiple recessions, technological disruptions, global crises, and changing business cycles will find a way to adapt once again.

Hope that decades of accumulated experience, strong balance sheets, talented employees, and capable management teams still matter. Hope that they too will adopt AI and keep growing!

Life itself often runs on hope.

Parents invest in their children’s education with hope.
Entrepreneurs build businesses with hope.
Farmers sow seeds with hope.
Patients undergo treatment with hope.

Hope gives us the courage to act when certainty is unavailable.

But hope alone is not enough.
In investing, hope must eventually be supported by facts, valuation, earnings, and sound judgment.

Today, I bought these stocks with hope.

Time will tell whether that hope was justified.

Caution: Hope is no strategy in investing.

https://t.co/Lz23zJQV8Z

#investing

[sandip sabharwal @sandipsabharwal]

#Nifty still has 5 IT stocks, however the weightage has come down to around 8.5% from 16% in 2021.
The crack in these stocks is the main reason for the Nifty decline today.
Most likely some of these stocks will move out of the Nifty sooner than later

Indian Markets remain a BUY on DIPs as longer term prospects are improving with moderating macro concerns

[Pulse Of Profit @PULSEOFPROFIT10]

Major IPOs in Pipeline

[Venkatesh @SuccessProject_]

If you are new to Investing and wish to study FINANCIAL STATEMENT ANALYSIS, Prof Anil K Sharma videos are the right place to start.

60 lectures on the topic.

https://t.co/WwUu2GjG2N

[Markets by Zerodha @zerodhamarkets]

NSE filed its IPO papers this week. At nearly ₹30,000 crore, it may well become the biggest IPO India has ever seen. NSE is the reason we exist, and so does every other broker in India. Their offer document is a gold mine. Here's what stood out.🧵👇

[Kyro Ventures Research @kyroventures]

India's CRDMO industry is an ~$8 billion business sitting inside a ~$200 billion global market.

That gap is the entire thesis.
It grows ~1.5× the global rate, holds under 4% share against China's ~8%, and sits at the receiving end of a global supply realignment. The headroom — not the base — is the story.

We've torn the whole sector down, end to end:

* The market math — $8.2B today → ~$15B by 2029E (~14% CAGR), and where the GLP-1 API and biologics pools open up
* The molecule mix — small molecules still ~72%, but biologics & peptides compounding at ~2× the rate
* The value chain — why margin concentrates at the two ends (discovery IP + complex commercial chemistry earn 30–40%) while commodity mid-chain API deflates
* Who actually plays each link — Syngene, Divi's, Laurus, Gland, Piramal, Blue Jet, Cohance and more, mapped stage by stage

24 molecules. 13 CDMOs. One complete picture.

📖 Read the full report at https://t.co/E7oSZoMYv3 — our most comprehensive sector teardown yet.

[AIM Investments @AimInvestments]

IT-> Pharma/Healthcare movement will accelerate further

[Shri Siddhivinayak Temple 🪷 @MoryaVibes]

गणपती बाप्पा मोरया🌸 मंगलमूर्ती मोरया
🙏Ganapati Bappa Moraya🌸
🙏Mangalmurti Moraya
19/06/2026